DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

Information source: St. Joseph's Hospital and Medical Center, Phoenix
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Preterm Labor

Intervention: Experimental: Vaginal progesterone (Drug); Experimental: Topical progesterone (Drug); Experimental: Intramuscular progesterone (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: St. Joseph's Hospital and Medical Center, Phoenix

Official(s) and/or principal investigator(s):
James Balducci, MD, Principal Investigator, Affiliation: St. Joseph's Hospital and Medical Center, Phoenix
Robert Garfield, PhD, Principal Investigator, Affiliation: St. Joseph's Hospital and Medical Center, Phoenix

Overall contact:
James Balducci, MD, Phone: 602-406-3691, Email: James.Balducci@dignityhealth.org


This study will examine the effects of various formulations of progesterone on uterine electromyographic (EMG) activity in pregnant patients in premature labor to determine if progesterone will suppress uterine electrical activity and which formulation may be best for inhibition of uterine activity. Patients will be monitored prior to treatment and following treatment (every 2 to 4 hours) with one of three different formulations of progesterone for up to two days. Patients will continue to be observed until they deliver. Comparisons will be for uterine EMG activity from before treatment to that following treatments at 2, 4, 8, 12 24 and 48 hours and times of delivery after treatments (hours or days following treatments). Comparisons between mean values for EMG activity between the various treatments at the various times will also be made.

Clinical Details

Official title: Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Inhibition of uterine electromyographic (EMG) activity by various formulations of progesterone.

Secondary outcome: Effects of progesterone on uterine EMG activity and preterm birth

Detailed description: In this study the investigators will compare the effects of vaginal progesterone, intramuscular applied progesterone and topical progesterone on uterine electromyographic activity (EMG)in patients in preterm labor. Electrodes will be placed on the abdominal surface of pregnant patients in preterm labor and the EMG activity recorded for 30 minutes before and following treatments for up to 48 hours. In addition data on delivery times will be recorded when patients delivery vaginally or by Cesarian section. Eligibility criteria: Healthy patients without infection or rupture of membranes with gestational ages between 24 to 34 weeks. Outcome measures: Comparisons of uterine EMG activity (EMG amplitude, frequency, and specific information on EMG bursts) from measurements before treatment to following treatments with progesterone preparations at various times (at 2,4,8, 12,24 and to 48 hours following treatment) and delivery times of patients on various treatments (hours or days following treatments, average delivery times in patients treated by various formulations). Comparisons of mean values in uterine EMG activity (EMG amplitude, burst frequency and frequency of signals in a burst, power spectrum analysis of the bursts and peak power density spectrum of bursts) from before treatment to following treatments at 2 to 24 hours will be compared. Also the time of delivery following treatments will be obtained and the average time of delivery following the various treatments compared.


Minimum age: 17 Years. Maximum age: 40 Years. Gender(s): Female.


Inclusion Criteria:

- Healthy patients in preterm labor between 24 to 34 weeks of gestation presenting to

St. Joseph's Hospital and Medical Center.

- Preterm labor is defined as at least 6 contractions in 60 minutes with a cervix

either dilated to 2 centimeters or effaced to 80% and a cervical length measured by ultrasound of less than 3 centimeters, and a positive fetal fibronectin.

- Maternal ages will be within 17 to 40 year-old range.

Exclusion Criteria:

- Patients with preterm premature rupture of membranes (PPROM) will be excluded from

the study, due to possibility of ascending infection, as will those patients with suspected chorioamnionitis.

- Patients with medical conditions that contraindicate tocolysis, such as

non-reassuring fetal heart tracings, will also be excluded.

Locations and Contacts

James Balducci, MD, Phone: 602-406-3691, Email: James.Balducci@dignityhealth.org

St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, United States; Recruiting
James Balducci, MD, Phone: 602-406-3691, Email: james.balducci@dignityhealth.org
Robert Garfield, PhD, Phone: 602-708-7617, Email: robert.garfield@dignityhealth.org
James Balducci, MD, Principal Investigator
Robert Garfield, Sub-Investigator
Additional Information

Related publications:

Kuon RJ, Shi SQ, Maul H, Sohn C, Balducci J, Maner WL, Garfield RE. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol. 2010 May;202(5):455.e1-9. doi: 10.1016/j.ajog.2010.03.025.

Lucovnik M, Kuon RJ, Chambliss LR, Maner WL, Shi SQ, Shi L, Balducci J, Garfield RE. Use of uterine electromyography to diagnose term and preterm labor. Acta Obstet Gynecol Scand. 2011 Feb;90(2):150-7. doi: 10.1111/j.1600-0412.2010.01031.x. Epub 2010 Dec 7. Review.

Kuon RJ, Shi SQ, Maul H, Sohn C, Balducci J, Shi L, Garfield RE. A novel optical method to assess cervical changes during pregnancy and use to evaluate the effects of progestins on term and preterm labor. Am J Obstet Gynecol. 2011 Jul;205(1):82.e15-20. doi: 10.1016/j.ajog.2011.02.048. Epub 2011 Feb 23.

Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011 Jul;38(1):18-31. doi: 10.1002/uog.9017. Epub 2011 Jun 15.

Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, Garfield RE. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008 Oct;199(4):391.e1-7. doi: 10.1016/j.ajog.2008.06.085.

Starting date: July 2011
Last updated: March 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017